CG Oncology (CGON) Other Operating Expenses (2025 - 2026)

CG Oncology (CGON) posted Other Operating Expenses of $3.0 million for Q1 2026, down 3.52% on a QoQ basis from $3.1 million in Q4 2025.

CG Oncology (CGON) Other Operating Expenses (2025 - 2026) Analysis & Trends

CG Oncology's Other Operating Expenses history runs 2 years deep, the most recent figure standing at $3.0 million for Q1 2026.

Quarterly Other Operating Expenses changed N/A year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (changed N/A YoY) and the FY2025 annual result came in at $4.6 million, changed N/A from the prior year.
Other Operating Expenses was $3.0 million for Q1 2026 at CG Oncology, down from $3.1 million in the prior quarter.
Across five years, Other Operating Expenses topped out at $3.1 million in Q4 2025 and bottomed at $1.6 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	CG Oncology	5.86 Bn	5.86 Bn	-1.88 Mn

Download Data